Institut de Recherche Biomedicale des Armees   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Brétigny-sur-Orge France (2009)

Organization Overview

First Clinical Trial
2015
NCT03182413
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Institut de Recherche Biomedicale des Armees | Marion Trousselard

Active Ingredients

Drugs in Phase 3 Trials (3)

blood plasma (1 trial)

risperidone (risperdal) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 1 Trials (1)

modafinil (provigil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 3)

Blood Coagulation Disorders (Phase 3)

Hemostatic Disorders (Phase 3)

Shock (Phase 3)

Shock, Hemorrhagic (Phase 3)

Sleep Deprivation (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4